$VTAK Catheter Precision, Inc. (NYSE American:VTAK)

New Post Public Reply Private Reply Replies (0) Message Board
louied91
157
$VTAK Catheter Precision, Inc. (NYSE American:VTAK) Releases Operational Performance Report, Q4 and Annual 2023 Financials for Year Ending December 31, 2023

https://www.accesswire.com/848710/catheter-pr...er-31-2023

FORT MILL, SC / ACCESSWIRE / April 1, 2024 / Catheter Precision, Inc. (NYSE-American:VTAK), a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product(s), releases Q4 and Annual Financials, Operational Report for year ending 2023, showcasing substantial revenue growth rate year over year. Additionally, the company makes strides, achieves milestones, etc., in clinical data and intellectual property advancements in cardiac electrophysiology sector.

2023 Fourth Quarter and Annual Financial Results are as follows:

Total assets as of December 31, 2023 were $30.7 million.
Total cash on hand as of December 31, 2023 was $3.6 million.
Total revenues for the year ended December 31, 2023 were $442 thousand.
Shareholders equity as of December 31, 2023 was $21.2 million.
Net loss for the year ended December 31, 2023 was ($70.6) million. A one-time $60.9 million write off for impairment of goodwill is reflected in the net loss for the year ended December 31, 2023.
Revenue for the fourth quarter of 2023 totaled $128.8 thousand, compared to zero in the prior year fourth quarter. Revenue for the full year 2023 totaled $442 thousand, compared to $14 thousand in 2022.

Gross margin for the fourth quarter and full year 2023 were approximately 94% and 93% of revenue, respectively. Operating expenses in the fourth quarter were $2.7 million. Operating expenses for the full year 2023 were $78.5 million, which includes the one-time write off for impairment of goodwill of $60.9 million, compared to $26.8 million in the prior year.

Net loss for the fourth quarter of 2023 was ($0.7) million, compared to ($8.2) million in the previous year. For the full year 2023, net loss was ($70.6) million, which includes the one-time write off for impairment of goodwill of $60.9million, compared to a net loss of ($26.9) million, which includes the one-time write off for restructuring costs of $4.1 million, in the prior year. Decrease in cash and cash equivalents for the full year 2023 was ($12.3) million compared to an increase for the full year 2022 of $0.8 million.

"We made significant progress in 2023", said David Jenkins, CEO of Catheter Precision. "First, we acquired a private electrophysiology company and realigned our products and operations moving forward to focus on Catheter Precision's historical cardiac electrophysiology business. Secondly, we brought in additional third-party financing to allow us to bring our products out to the market in a limited release. 2023 was a transitional year for us and going into 2024 we believe we are well positioned to fortify our sales efforts. We are now engaging a number of key institutional hospitals as we demonstrate the utility of our products, including their cost effectiveness. We remain quite excited about the growth and opportunities within our field of cardiac electrophysiology.

Clinical Progress

During the year Catheter Precision concluded enrollment of 125 patients in its VIVO European Registry enrollment. The data are positive for demonstration of effectiveness of VIVO, and details of the registry are in the process of being finalized for publication. VIVO is our product for non-invasive localization of ventricular arrhythmias, used to guide ablation procedures in a more effective and timely manner. Likewise, our initial clinical trial for LockeT, our closure device, with over 100 patients, has been concluded, also with positive and competitive data. Details are in a manuscript form and have been submitted for publication. We are well into our second clinical trial for LockeT which we expect to be concluded in mid-year of this year.

Intellectual Property

Over the course of the year, Catheter Precision, Inc. has filed 8 patent applications and received 6 patent issuances. "We continue to be aware of an evolving landscape in MedTech designs and applications, and, as such, will continue to file and prosecute patents throughout the global marketplace", continued David Jenkins.

Ra Medical Systems Inc. (RMED) Stock Research Links

RMED Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 151

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
LONGWELL's New Axial Fan Selection Guide Unveiled

Updated Category News Views 88

LONGWELL's New Fan Brochure Shakes Up Data Center Cooling Alright, let's cut to the chase. LONGWELL, the folks out in Ningbo who live and breathe HVACR and industrial fans, have dropped a new tool that’s going to have OEM engineers raising a glass. This twelve-page axial fan selection guide is a stroke of genius—or at least that's what those of us who've braved the...

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 113

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 89

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 82

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 122

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Asia-Pacific Miracle: New Economic Chapter Unfolds

Updated Category News Views 147

A Fresh Breeze in Asia-Pacific's Sails You ever look around and realize everything's about to change—again? That's Asia-Pacific right now. We're staring down the barrel of a new chapter in what folks are calling the "Asia-Pacific miracle." The text from China Daily paints a picture of a region gearing up to crank the cooperation dial even higher. And where's this...

Continue Reading
Investors, Portillo's Fraud Claims Demand Your Attention

Updated Category News Views 30

Portillo's Investors Caught in a Tough Spot Ah, Portillo's. You thought those hot dogs were the only spicy thing you're biting into? Try these allegations on for size. Investors are biting back with a securities fraud lawsuit, and the details are saltier than a bucket of fries. The folks who held PTLO shares between September 19, 2023, and May 4, 2026, are in the...

Continue Reading
Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 92

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 125

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

Ocean Power Technologies Enhances Market Reach with New Partnership

Updated Category News Views 124

Expanding Horizons in Latin America Ocean Power Technologies, Inc. (NYSE American: OPTT), a pioneer in low-carbon marine power solutions, has taken a significant step in expanding its operational footprint by signing a reseller agreement in Latin America. This significant partnership primarily targets the offshore and maritime sectors in Mexico. A New Partnership for...

Continue Reading
Aktsiaselts Infortar's Strategic Move in the Polish Energy Sector

Updated Category News Views 121

Aktsiaselts Infortar Expands Into Poland's Energy Market Aktsiaselts Infortar, through its wholly owned subsidiary AS Eesti Gaas, has taken a significant step in its growth strategy by acquiring 100% of EWE Polska sp. z o.o., an important player in the Polish energy sector. This strategic acquisition enables Infortar to broaden its operational footprint beyond the...

Continue Reading
Exciting Insights Await at Can-Fite's Live Investor Webinar

Updated Category News Views 151

Join Can-Fite BioPharma's Informative Live Investor Webinar Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is thrilled to announce an exclusive live investor webinar aimed at sharing vital insights into their innovative drug pipeline. This engaging session will take place on a Tuesday afternoon, providing an excellent opportunity for investors and stakeholders...

Continue Reading
Ajinomoto Co. Partners with LabCentral to Boost Biotech Innovation

Updated Category News Views 365

Ajinomoto Co., Inc. Enhances Biotech Innovation Ajinomoto Co., Inc., a prominent player in biotechnology and food innovation, recently unveiled its full-scale support for LabCentral, a distinguished platform for startups in the biosciences sector. This initiative reaffirms the Ajinomoto Group's dedication to innovation and collaborative growth within an ever-evolving...

Continue Reading
ATI Physical Therapy's Strategic Shift to Private Ownership

Updated Category News Views 610

ATI Physical Therapy Shifts to Private Ownership ATI Physical Therapy, Inc. (OTC: ATIP), known for its outstanding outpatient physical therapy and rehabilitation services, has made a significant transition. In a recent announcement, the company disclosed its evolution from public to private ownership, led by a consortium of existing shareholders including Knighthead...

Continue Reading